Maria Gabriella Brasca
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Heat shock proteins research, Computational Drug Discovery Methods, Microtubule and mitosis dynamics, Advanced Breast Cancer Therapies
Most-Cited Works
- → 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding(2004)159 cited
- → Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor(2009)126 cited
- → 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization(2005)108 cited
- → NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor(2011)104 cited
- → A highly convergent total synthesis of the spiroacetal macrolide (+)-milbemycinβ1(1989)93 cited
- → Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors(2010)81 cited
- → The Synthesis of Azadirachtin: A Potent Insect Antifeedant(2008)64 cited
- → Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing(2010)62 cited
- → Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy(2010)61 cited
- → 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors(2005)57 cited